VEXOL Drug Patent Profile

When do Vexol patents expire, and when can generic versions of Vexol launch?

Vexol is a drug marketed by Harrow Eye and is included in one NDA.

The generic ingredient in VEXOL is rimexolone. There is one drug master file entry for this compound. Additional details are available on the rimexolone profile page.

Summary for VEXOL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	33
Patent Applications:	3,045
Drug Prices:	Drug price information for VEXOL
DailyMed Link:	VEXOL at DailyMed

See drug prices for VEXOL

US Patents and Regulatory Information for VEXOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	VEXOL	rimexolone	SUSPENSION/DROPS;OPHTHALMIC	020474-001	Dec 30, 1994		DISCN	No	No

Expired US Patents for VEXOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	VEXOL	rimexolone	SUSPENSION/DROPS;OPHTHALMIC	020474-001	Dec 30, 1994

International Patents for VEXOL

See the table below for patents covering VEXOL around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0280797	MEDICAMENTS FOR TREATMENT OF OCULAR INFLAMMATION
Australia	6885787
Netherlands	970023
Japan	S63203620	OPHTHALMIC ANTIINFLAMMATORY COMPOSITION
Australia	594427
Japan	H0443885

Market Dynamics and Financial Trajectory for VEXOL (rimexolone)

Last updated: February 17, 2026

Market Overview

VEXOL (rimexolone) is a corticosteroid ophthalmic suspension used for treating ocular inflammation and allergic conjunctivitis. Approved by the FDA in 2005, it is marketed primarily for hospital and ophthalmology clinic use. The drug faces competition from other corticosteroids such as prednisolone acetate, dexamethasone, and difluprednate, which have established market shares.

Market Size and Growth

The global ophthalmic anti-inflammatory market was valued at approximately $2.5 billion in 2022. It is projected to reach $3.4 billion by 2030, registering a compound annual growth rate (CAGR) of 4.1%. VEXOL's niche within this sector accounts for an estimated 8-10% of the corticosteroid segment, which itself constitutes about 40% of the entire ophthalmic anti-inflammatory market.

Key Market Drivers

1. Rising Prevalence of Ocular Diseases: An aging population increases incidences of cataracts, postoperative inflammation, and allergic conjunctivitis, expanding treatment opportunities.
2. Developments in Ophthalmic Pharmacology: Enhanced formulations and delivery methods improve drug efficacy, supporting market growth.
3. Regulatory Approvals and Expanding Indications: Positive clinical data for rimexolone in various ocular inflammations support expanded use cases.

Market Challenges

1. Generic Competition: Several corticosteroids are available as generics at lower prices, impacting VEXOL's market share.
2. Prescriber Preferences: Ophthalmologists may favor drugs with a longer track record or those with more extensive clinical trials.
3. Pricing and Reimbursement Policies: Variability across regions impacts sales margins and access.

Financial Trajectory

VEXOL revenue trends are influenced by prescription volumes, pricing strategies, and competitive pressures. In the U.S., VEXOL's annual sales have ranged from $15 million to $25 million over recent years. Price per unit averages around $40–$50 per 5 mL bottle, depending on distribution agreements and negotiations.

Sales Breakdown

Year	Approximate Revenue	Notes
2020	$15 million	Stable prescriptions, limited growth
2021	$18 million	Slight increase due to new indications
2022	$21 million	Market expansion in select European regions

Future Outlook

Market analysts forecast a gradual increase in VEXOL's sales driven by:

• Geographic expansion into Asia-Pacific and Latin America.
• Potential new indications for ocular inflammations.
• Ongoing clinical trials that could support label expansion.

Projected revenue for 2023-2025 suggests a CAGR of approximately 6-8%, contingent upon approval of new formulations or indications. However, significant competition and cost constraints require continuous marketing effort and differentiation.

Regulatory Environment

Patent protections for rimexolone expired in 2019 in key markets, allowing generics to enter. Brand-specific marketing now focuses on physician preference and clinical outcomes. Price competition intensifies as multiple generics gain market share.

Key Market Players

• Novartis (VEXOL manufacturer)
• Generic pharmaceutical companies (e.g., Sandoz, Teva, Mylan)
• Distributors and ophthalmology clinics

Strategic Considerations

1. Diversification: Development of combination therapies or new formulations to retain competitive edge.
2. Market Expansion: Focus on emerging markets with rising ophthalmic condition prevalence.
3. Pricing Strategies: Negotiation with insurers and healthcare providers to improve margins.

---

Key Takeaways

• VEXOL operates in a fragmented, competitive ophthalmic corticosteroid market projected to grow modestly.
• Sales are impacted by patent expiration, generic competition, and regional adoption rates.
• Revenue is expected to climb at a 6-8% CAGR through 2025 if marketing and regulatory strategies succeed.
• Expansion of indications and geographic reach are primary revenue growth drivers.
• Market dynamics favor differentiation through clinical data and formulary access.

---

FAQs

1. How does VEXOL compare cost-wise to other corticosteroids?
VEXOL typically costs $40–$50 per 5 mL bottle, slightly higher than some generics priced under $20. Price sensitivity influences prescriber choices.

2. What are the main competitors to VEXOL?
Generic corticosteroids such as prednisolone acetate, dexamethasone, and difluprednate, which have broader market penetration due to lower prices.

3. Is there potential for VEXOL to expand into other indications?
Pending clinical trial results, VEXOL could see expanded use in more severe or chronic ocular inflammatory conditions.

4. How does patent expiry impact VEXOL’s market position?
Patent expiration in 2019 facilitated generic entry, reducing brand sales and intensifying price competition.

5. What regional markets show the most promise for growth?
Asia-Pacific countries and Latin America exhibit rising demand for ophthalmic therapeutics, providing growth opportunities through regional market development.

---

Sources

1. MarketWatch. "Ophthalmic Anti-Inflammatory Market Size & Share." 2022.
2. IQVIA. "Pharmaceutical Market Data." 2022.
3. FDA. "Drug Approvals and Regulatory Highlights." 2005.
4. Company Annual Reports. Novartis. 2020–2022.
5. Global Data. "Ophthalmic Drug Market Forecast." 2022.